Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a complex, progressive primary neurodegenerative disease. Since pivotal genetic studies in 1993, the ε4 allele of the apolipoprotein E gene (APOE ε4) has remained the strongest single genome-wide associated risk variant in AD. Scientific advances in APOE biology, AD pathophysiology and ApoE-targeted therapies have brought APOE to the forefront of research, with potential translation into routine AD clinical care. This contemporary Review will merge APOE research with the emerging AD clinical care pathway and discuss APOE genetic risk as a conduit to genomic-based precision medicine in AD, including ApoE’s influence in the ATX(N) biomarker framework of AD. We summarize the evidence for APOE as an important modifier of AD clinical–biological trajectories. We then illustrate the utility of APOE testing and the future of ApoE-targeted therapies in the next-generation AD clinical–diagnostic pathway. With the emergence of new AD therapies, understanding how APOE modulates AD pathophysiology will become critical for personalized AD patient care. This Review provides a framework for incorporating APOE into Alzheimer’s disease (AD) clinical care by bridging recent advances in APOE and AD research with emerging clinical applications for APOE testing and ApoE-targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“However, switching from the APOE ε4 to the APOE ε2 allele could have deleterious consequences in the periphery given the association with type III hyperlipoproteinemia 12 (Fig.”
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“Furthermore, [ 18 F]fluorodeoxyglucose PET measures showed that APOE ε4 carriers had lower cerebral glucose metabolism, correlating with Aβ pathology, brain atrophy and cogni tive measures across multiple stages of AD 115 .”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277 · cited 1×
“Since the first genomewide association studies in AD, at least 75 risk loci in addition to APOE have been associated with AD 138,139 , which can be incorporated in the PRS to improve AD risk determination 130,131 .”
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Self-citationProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 2×
“By contrast, APOE ε2 remains the strongest genetic protective factor against sporadic AD 7,8 , with very few APOE ε2 / ε2 individuals developing AD up to the age of 90 years 14,18 .”
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 12×
“A small percentage of EOAD is caused by familial autosomal dominant mutations (ADAD; autoso mal dominant AD), while the morecommon LOAD is attributed to a combination of genetic susceptibility and environmental factors 4 .”
InfluentialAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · cited 2×
“APOE ε4 carriers show changes in multiple vascular biomarkers, including decreased cerebral blood flow, increased BBB breakdown, more white matter intensities, evidence of CAA and increased levels of CSF sPDGFRβ 105,106 .”
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 4×
“4a), there is an APOE ε4 > ε2 > ε3 effect on the onset and extent of Aβ deposition in animal models 31,32,57 .”
InfluentialSelf-citationApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 6×
“In vitro and mouse model studies have shown that ApoE4 increases tau hyperphospho rylation and aggregation 48,79,80 , causing neurodegeneration in the absence of Aβ as mediated by microglial activation 48,79,80 (Fig.”
InfluentialSelf-citationLin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037 · cited 9×
“Another therapeutic approach for ApoE has been using gene therapy to switch APOE isoforms from APOE ε4 to the protective APOE ε2 allele 23 .”
InfluentialLecanemab: Appropriate Use Recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.30 · Cited by 961 · cited 2×
“…therapies now suggest including APOE testing as part of treatment prescription (https://www.accessdata.fda.gov/drugsatfda_docs/ label/2023/761269Orig1s001lbl.pdf) 124 , APOE testing will become more prevalent as these therapies become more widely available in the maturing AD clinical care pathway.”
Self-citationCerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947 · cited 9×
“APOE ε4 carriers have the highest risk of CAA due to higher Aβ deposition in vessels leading to microbleeds, while APOE ε2 carriers have a higher risk of hemorrhage from CAA if present, given that vessels are more prone to rupture 103 (Fig.”
InfluentialHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“4a), there is an APOE ε4 > ε2 > ε3 effect on the onset and extent of Aβ deposition in animal models 31,32,57 .”
Self-citationAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Self-citationTREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge
Nugent, A. A., Lin, K., van Lengerich, B., Lianoglou, S., Przybyla, L., Davis, S. S., Llapashtica, C., Wang, J., Kim, D. J., Xia, D., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.007 · Cited by 798
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 2×
“The Aβmediated effect of ApoE on vascular dysfunction may be linked to Aβ clearance across the BBB in APOE ε4 carriers, with perivascular accumulation of Aβ 57,63,65 lead ing to CAA with vessel wall breakdown and hemorrhage (Fig.”
Self-citationAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis
Neu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S. P., Redolfi, A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2188 · Cited by 674
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man
UTERMANN, G., HEES, M., & STEINMETZ, A. (1977) · Nature · doi:10.1038/269604a0 · Cited by 666 · cited 1×
“Originally identified and associated with a specific form of lipid disorder, APOE is also associated with dysbetalipoproteinemia 17 .”
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMolecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617 · cited 1×
“The APOE ε4 allele also increases the risk of EOAD, particularly in homozygous individuals without a family history and in APOE ε4 carriers with a positive family history 24,25 .”
Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy
Chen, X., Firulyova, M., Manis, M., Herz, J., Smirnov, I., Aladyeva, E., Wang, C., Bao, X., Finn, M. B., Hu, H., et al. (2023) · Nature · doi:10.1038/s41586-023-05788-0 · Cited by 609 · cited 2×
“APOE ε4 expression causes aberrant cholesterol accumulation in oligodendrocytes, result ing in reduced myelination 99 , and microgliamediated infiltrating T cells also affect taumediated neurodegeneration in APOE ε4 expressing mice 92 (Fig.”
Self-citationApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608 · cited 1×
“ApoE’s direct binding to Aβ in vitro is dependent on isoform, cellular source, lipidation status and Aβ species 62 , although the in vivo physiological relevance of these factors remains unclear.”
Arboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0611-3 · Cited by 598 · cited 1×
“…explanation, a previous study showed that the APOE3 Christchurch mutation in a homozygous state was associ ated with a 30year delay in cognitive decline in one individual carrier with the PSEN1(E280A) mutation 29 , with evidence of Aβ deposition but attenuated tau pathology and inflammation 30 .”
Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570 · cited 3×
“https://doi.org/10.1038/s41593-024-01669-5 have an increased risk of progression to the next stage of the AD con tinuum, while APOE2 carriers have a lower risk of progression 41,42 , prob ably owing to the earlier onset of Aβ pathology 43 .”
InfluentialLoss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deussing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0296-9 · Cited by 555 · cited 1×
“Micro glia may contribute to codeposition of ApoE in amyloid plaques as part of a TREM2dependent response 89,90 .”
Self-citationApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion
Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017) · Cell · doi:10.1016/j.cell.2016.12.044 · Cited by 528 · cited 1×
“66).”
APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes
Blanchard, J. W., Akay, L. A., Davila-Velderrain, J., von Maydell, D., Mathys, H., Davidson, S. M., Effenberger, A., Chen, C.-Y., Maner-Smith, K., Hajjar, I., et al. (2022) · Nature · doi:10.1038/s41586-022-05439-w · Cited by 496 · cited 1×
“APOE ε4 expression causes aberrant cholesterol accumulation in oligodendrocytes, result ing in reduced myelination 99 , and microgliamediated infiltrating T cells also affect taumediated neurodegeneration in APOE ε4 expressing mice 92 (Fig.”
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473 · cited 5×
“By contrast, APOE ε2 remains the strongest genetic protective factor against sporadic AD 7,8 , with very few APOE ε2 / ε2 individuals developing AD up to the age of 90 years 14,18 .”
InfluentialSelf-citationApoE4 Accelerates Early Seeding of Amyloid Pathology
Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.013 · Cited by 451 · cited 1×
“The APOE ε4 allele accelerates the initial seeding and formation of Aβ plaques but with little effect on amyloid accumula tion after plaque deposition begins 58 .”
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412 · cited 3×
“ARIA is a treatmentemergent imaging abnormality that occurs with the use of antiAβ monoclonal antibodies that bind to aggregated forms of Aβ, characterized by parenchymal edema and sul cal effusions or microhemorrhages and hemosiderin deposition 103,114 .”
Self-citationCholesterol and matrisome pathways dysregulated in astrocytes and microglia
TCW, J., Qian, L., Pipalia, N. H., Chao, M. J., Liang, S. A., Shi, Y., Jain, B. R., Bertelsen, S. E., Kapoor, M., Marcora, E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.017 · Cited by 411 · cited 2×
“Deletion of APOE or the APOE ε4 isoform promotes an accumulation of lipids in astrocytes and microglia 95–97 .”
Self-citationGoldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383 · cited 2×
“APOE ε4 carriers have increased levels of CSF ptau and plasma ptau 217 and ptau 181 , which is likely to be related to the earlier brain deposition of Aβ 50,55,72 .”
Self-citationApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism
Qi, G., Mi, Y., Shi, X., Gu, H., Brinton, R. D., & Yin, F. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108572 · Cited by 379 · cited 1×
“https://doi.org/10.1038/s41593-024-01669-5 gliamediated neurodegeneration 96,98 (Fig.”
InfluentialPhenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.
Linton, M. F., Gish, R., Hubl, S. T., Bütler, E., Esquivel, C., Bry, W. I., Boyles, J. K., Wardell, M. R., & Young, S. G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115288 · Cited by 367 · cited 16×
“As BBBM tests become more widely used in clinical practice, they may also provide APOE status results, possibly circumventing the need for separate APOE testing.”
InfluentialTolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354 · cited 1×
“Growing evidence shows that APOE genotype plays a role in the risks and benefits of new AD therapies 126 , with variable risks and benefits in APOE ε4 carriers 126 , which may influence clinical decisions on which therapy is appropriate for APOE ε4 carriers versus noncarri ers.”
Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., Manis, M., Schroeder, C., Yin, Z., Madore, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.03.024 · Cited by 334 · cited 3×
“In vitro and mouse model studies have shown that ApoE4 increases tau hyperphospho rylation and aggregation 48,79,80 , causing neurodegeneration in the absence of Aβ as mediated by microglial activation 48,79,80 (Fig.”
InfluentialSelf-citationApolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327 · cited 2×
“117), increased neurotoxic Aβ oligomers at synapses with synapse loss 59 and loss of synaptic proteins leading to impaired synaptic transmission 4 (Fig.”
Self-citationAPOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
Belloy, M. E., Andrews, S. J., Le Guen, Y., Cuccaro, M., Farrer, L. A., Napolioni, V., & Greicius, M. D. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3599 · Cited by 320 · cited 7×
“By contrast, APOE ε2 remains the strongest genetic protective factor against sporadic AD 7,8 , with very few APOE ε2 / ε2 individuals developing AD up to the age of 90 years 14,18 .”
InfluentialLipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity
Victor, M. B., Leary, N., Luna, X., Meharena, H. S., Scannail, A. N., Bozzelli, P. L., Samaan, G., Murdock, M. H., von Maydell, D., Effenberger, A. H., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.005 · Cited by 316
Lipid Accumulation Induced by APOE4 Impairs Microglial Surveillance of Neuronal-Network Activity
Victor, M. B., Leary, N., Luna, X., Meharena, H. S., Bozzelli, P. L., Samaan, G., Murdock, M. H., von Maydell, D., Effenberger, A. H., Cerit, O., et al. (2022) · doi:10.1101/2022.03.21.484146 · Cited by 311 · cited 2×
“ApoE4 impairs cholesterol transport out of microglia and increases cholesterol synthesis in astrocytes 95,97 , leading to proinflammatory signaling 96,97 , impaired astrocytic and microglial function and”
InfluentialApoE facilitates the microglial response to amyloid plaque pathology
Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171265 · Cited by 297
Self-citationApolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294 · cited 1×
“In humans, APOE ε4 carriers have greater amounts of soluble Aβ oligomers 59,60 , with ApoE4 increasing Aβ oligomerization in vitro 60 , while ApoE2 and ApoE3 inhibit the conver sion of protofibrils into fibrils 61 .”
Self-citationHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Self-citationFryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278 · cited 1×
“…APOE in Aβtransgenic mice prevented the formation of CAA and associated microhemorrhages 109 , while expression of human APOE ε4 resulted in redistribution of Aβ from plaques to the vessels forming CAA 110 , and removing astrocytic APOE ε4 shifted Aβ depo sition from plaques to CAA 111 .”
Self-citationBuckley, R. F., Mormino, E. C., Amariglio, R. E., Properzi, M. J., Rabin, J. S., Lim, Y. Y., Papp, K. V., Jacobs, H. I. L., Burnham, S., Hanseeuw, B. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.010 · Cited by 276 · cited 1×
“Female APOE ε4 carriers undergo agerelated cognitive decline faster than men across the AD conti nuum, probably owing to underlying Aβ pathology 46 .”
Self-citationAPOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease
Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255 · cited 2×
“Diseaseassociated microglia (DAM) or microglia of neurodegenerative phenotypes increase APOE expression 83 (Fig.”
Self-citationSeo, D.-O., O’Donnell, D., Jain, N., Ulrich, J. D., Herz, J., Li, Y., Lemieux, M., Cheng, J., Hu, H., Serrano, J. R., et al. (2023) · Science · doi:10.1126/science.add1236 · Cited by 254 · cited 1×
“Gut microbiota may mediate gliosis in tauopathy mice, as a potential link between dietary factors and ApoE - mediated neurodegeneration 81 .”
Self-citationThe role of APOE in cerebrovascular dysfunction
Tai, L. M., Thomas, R., Marottoli, F. M., Koster, K. P., Kanekiyo, T., Morris, A. W. J., & Bu, G. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1547-z · Cited by 231 · cited 5×
“…neurovascular unit (neurons, astrocytes, brain endothelial cells (BECs), mural cells (vascular smooth muscle cells and pericytes) and endothelium) 105 . of Aβ or tau biomarker levels, APOE ε4 carriers have BBB breakdown observed by magnetic resonance imaging in the hippocampus and the medial…”
Influential(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetic Consortium (ADGC), Li, Z., Kapoor, M., Harari, O., Del-Aguila, J. L., Black, K., Carrell, D., Cai, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1685-y · Cited by 231
Self-citationDiagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease
Chatterjee, P., Pedrini, S., Ashton, N. J., Tegg, M., Goozee, K., Singh, A. K., Karikari, T. K., Simrén, J., Vanmechelen, E., Armstrong, N. J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12447 · Cited by 231 · cited 1×
“Based on these nonclinical data, human studies also investigated the link between APOE and neuroimmune biomarkers in AD, showing an association between plasma GFAP and APOE ε4 carrier status in indi viduals diagnosed with AD 100,101 .”
Self-citationImpact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226 · cited 3×
“APOE ε4 carriers have more tau tangles postmortem but only in the presence of Aβ 33,73 , while APOE ε2 was associated with lower burden of Aβmediated tau pathology 73,74 (Fig.”
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics
Migliore, L., & Coppedè, F. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00714-w · Cited by 217 · cited 2×
“…metabolism and cardiovascular risk, several studies have investigated the relationship between multiple environmental factors that interact with APOE to modulate AD risk 34 , where healthy diet was associated with a greater reduction of dementia risk in APOE ε4 noncarriers than in carriers 34 .”
Activated microglia mitigate Aβ-associated tau seeding and spreading
Gratuze, M., Chen, Y., Parhizkar, S., Jain, N., Strickland, M. R., Serrano, J. R., Colonna, M., Ulrich, J. D., & Holtzman, D. M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210542 · Cited by 215
Self-citationAge-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209 · cited 2×
“APOE antisense oligonucleotides (ASOs) may be effective in preclinical AD before the onset of plaques 141 but also later, as they have been shown to decrease taumediated neu rodegeneration 94 .”
Self-citationDesigning the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191 · cited 4×
“The AT(N) system has since been extended to define and stage AD across its entire spectrum 35 , describing the temporal sequence of underlying pathological changes before the clinically symptomatic stages.”
InfluentialSelf-citationAmyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189
Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007000 · Cited by 187
Xiong, M., Jiang, H., Serrano, J. R., Gonzales, E. R., Wang, C., Gratuze, M., Hoyle, R., Bien-Ly, N., Silverman, A. P., Sullivan, P. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7522 · Cited by 179 · cited 3×
“For example, antiApoE antibodies that bind specifically to amyloid plaques and CAA could be used in earlystage AD to reduce Aβ plaques and CAA to remove this pathology and reduce ARIA risk 140 .”
InfluentialSelf-citationAPOE ε2 is associated with milder clinical and pathological Alzheimer disease
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176 · cited 1×
“APOE ε2 remains protective against longitudinal Aβ accumulation, particularly in those without the APOE ε4 allele 52,53 , con firmed by neuropathological studies 33,54 .”
Liu, C.-C., Zhao, J., Fu, Y., Inoue, Y., Ren, Y., Chen, Y., Doss, S. V., Shue, F., Jeevaratnam, S., Bastea, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01127-0 · Cited by 168
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154
Self-citationThe endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo
Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140 · cited 1×
“67), ApoE had no effect on transcriptional regulation of APP in mouse models 68 or on APP or APP Cterminal fragments in vivo 57 .”
APOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139 · cited 1×
“…events, while expression of APOE ε2 in the CNS may have adverse con sequences given the association of APOE ε2 with CAArelated intracer ebral hemorrhage 103 , primary tauopathy 143 and possibly glaucoma 144 , necessitating monitoring for these events in future trials of these therapies.”
Shi, Y., Andhey, P. S., Ising, C., Wang, K., Snipes, L. L., Boyer, K., Lawson, S., Yamada, K., Qin, W., Manis, M., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.034 · Cited by 135 · cited 1×
“ApoE4 exacerbates taumediated neurodegeneration by increas ing microglial activation, infiltration of activated CD4 + and CD8 + T cells and expression of DAMassociated genes 48,80,92 , while reduction of ApoE decreases microgliosis and taumediated neurodegenera tion 93,94 (Fig.”
Self-citationNeuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132 · cited 1×
“4b) 75,82 .”
Fitz, N. F., Nam, K. N., Wolfe, C. M., Letronne, F., Playso, B. E., Iordanova, B. E., Kozai, T. D. Y., Biedrzycki, R. J., Kagan, V. E., Tyurina, Y. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23762-0 · Cited by 129 · cited 1×
“4b) 67,91 .”
APOE genotype and early β-amyloid accumulation in older adults without dementia
Lim, Y. Y., Mormino, E. C., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004336 · Cited by 125
Self-citationAPOE genotype and sex affect microglial interactions with plaques in Alzheimer’s disease mice
Stephen, T. L., Cacciottolo, M., Balu, D., Morgan, T. E., LaDu, M. J., Finch, C. E., & Pike, C. J. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0729-z · Cited by 115 · cited 1×
“4b) 87,88 .”
Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition
Leonenko, G., Shoai, M., Bellou, E., Sims, R., Williams, J., Hardy, J., Escott‐Price, V., & Initiative, T. A. D. N. (2019) · Annals of Neurology · doi:10.1002/ana.25530 · Cited by 114
Self-citationCruchaga, C., Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Ali, M., Beric, A., Gorijala, P., Kohlfeld, P., et al. (2023) · doi:10.21203/rs.3.rs-2814616/v1 · Cited by 112 · cited 1×
“Recent studies have also shown a correlation between APOE genotype and CSF and plasma NfL levels 40,116 .”
Self-citationWestern, D., Timsina, J., Wang, L., Wang, C., Yang, C., Phillips, B., Wang, Y., Liu, M., Ali, M., Beric, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01972-8 · Cited by 111
Self-citationSepulveda-Falla, D., Sanchez, J. S., Almeida, M. C., Boassa, D., Acosta-Uribe, J., Vila-Castelar, C., Ramirez-Gomez, L., Baena, A., Aguillon, D., Villalba-Moreno, N. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02467-8 · Cited by 92 · cited 1×
“…explanation, a previous study showed that the APOE3 Christchurch mutation in a homozygous state was associ ated with a 30year delay in cognitive decline in one individual carrier with the PSEN1(E280A) mutation 29 , with evidence of Aβ deposition but attenuated tau pathology and inflammation 30 .”
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91 · cited 3×
“APOE ε4 reduction using ASOs can also mitigate tau aggregation and tau-associated gliosis and neurodegeneration 94 .”
Self-citationAssociation of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies
Goldberg, T. E., Huey, E. D., & Devanand, D. P. (2020) · Nature Communications · doi:10.1038/s41467-020-18198-x · Cited by 82
APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Self-citationA “multi-omics” analysis of blood–brain barrier and synaptic dysfunction in APOE4 mice
Barisano, G., Kisler, K., Wilkinson, B., Nikolakopoulou, A. M., Sagare, A. P., Wang, Y., Gilliam, W., Huuskonen, M. T., Hung, S.-T., Ichida, J. K., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20221137 · Cited by 78 · cited 1×
“APOE ε4 expression in mice leads to early disruption in the BBB transcriptome, resulting in progressive BBB breakdown and loss of pericytes 107 , probably owing to peripheral ApoE, as liverexpressed ApoE4 impairs the cerebrovasculature, leading to synaptic dysfunction and worsened cognition 108 .”
Abushakra, S., Porsteinsson, A., Scheltens, P., Sadowsky, C., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Wang, P., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.26 · Cited by 75
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 74
Self-citationApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels
Steward, A., Biel, D., Dewenter, A., Roemer, S., Wagner, F., Dehsarvi, A., Rathore, S., Otero Svaldi, D., Higgins, I., Brendel, M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4038 · Cited by 67
Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4
Margeta, M. A., Letcher, S. M., Igo, R. P., Cooke Bailey, J. N., Pasquale, L. R., Haines, J. L., Butovsky, O., Wiggs, J. L., & for the NEIGHBORHOOD consortium (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.8.3 · Cited by 51 · cited 1×
“…events, while expression of APOE ε2 in the CNS may have adverse con sequences given the association of APOE ε2 with CAArelated intracer ebral hemorrhage 103 , primary tauopathy 143 and possibly glaucoma 144 , necessitating monitoring for these events in future trials of these therapies.”
Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Apolipoprotein E4 has extensive conformational heterogeneity in lipid-free and lipid-bound forms
Stuchell-Brereton, M. D., Zimmerman, M. I., Miller, J. J., Mallimadugula, U. L., Incicco, J. J., Roy, D., Smith, L. G., Cubuk, J., Baban, B., DeKoster, G. T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215371120 · Cited by 48 · cited 1×
“Recent studies showed that ApoE4 exhibits conformational heterogeneity in both lipidfree and lipidbound states 13 , which may further affect its function in recep tor binding.”
Marino, C., Perez‐Corredor, P., O'Hare, M., Heuer, A., Chmielewska, N., Gordon, H., Chandrahas, A. S., Gonzalez‐Buendia, L., Delgado‐Tirado, S., Doan, T. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13436 · Cited by 45 · cited 2×
“A recent anti-ApoE antibody mimicked the APOE Christchurch mutation by reducing ApoE–heparin sulfate proteoglycan (HSPG) interaction and ameliorating tau pathology in mice 145 , providing a novel approach combining genetics and antibodies for an ApoE-targeted therapy.”
APOE Antibody Inhibits Aβ‐Associated Tau Seeding and Spreading in a Mouse Model
Gratuze, M., Jiang, H., Wang, C., Xiong, M., Bao, X., & Holtzman, D. M. (2022) · Annals of Neurology · doi:10.1002/ana.26351 · Cited by 41 · cited 1×
“Removing ApoE–Aβ complexes may mitigate downstream Aβ-mediated tau seeding and spreading as shown in one study, suggesting that targeting this interaction can have effects on other AD pathophysiologies 147 .”
Self-citationAPOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
Bu, G. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00556-6 · Cited by 37 · cited 2×
“https://doi.org/10.1038/s41593-024-01669-5 p.R251G mutation 28 .”
InfluentialKunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citationGenetic architecture of plasma Alzheimer disease biomarkers
Bradley, J., Gorijala, P., Schindler, S. E., Sung, Y. J., Ances, B., the Alzheimer’s Disease Neuroimaging Initiative, T. H. C. P., Ertekin-Taner, N., Younkin, S., Golde, T., Price, N., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad087 · Cited by 20
Self-citationWalsh, T., Duff, L., Riviere, M. E., Tariot, P. N., Doak, K., Smith, M., Borowsky, B., Lopez Lopez, C., Arratia, P. C., Liu, F., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.27 · Cited by 18 · cited 1×
“If ongoing ADprevention trials using therapies that stratify based on APOE genotype show benefit 128 , APOE testing may have clinical utility in this population.”
Cited by
Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
“2 was the first and most significant LOAD risk locus identified in AD (Narasimhan et al. 2024).”
Wei, P., Lin, K., Chen, X., Fang, C., Qiu, L., Hu, J., & Chang, J. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70306 · Cited by 11
“The extensive involvement of APOE4 in AD has led some scholars to propose the “APOE Cascade Hypothesis” to address the impact of APOE4 on AD [24, 25].”
Perks, C. M., Barker, R. M., Alhadrami, M., Alkahtani, O., Gill, E., Grishaw, M., Harland, A. J., Henley, P., Li, H., O’Sullivan, E., et al. (2025) · Genes · doi:10.3390/genes16030331 · Cited by 11
“Despite a strong involvement, a lack of clarity regarding the mechanism may explain why, despite the very strong risk posed in people, treatments targeting ApoE have not been progressed to the same level as perhaps some others [99,100].”
Musso, G., Cosma, C., Moz, S., Gabelli, C., Navaglia, F., Codemo, A., Zambon, C. F., Cagnin, A., Antonini, A., Corbetta, M., et al. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120659 · Cited by 6
Metadata
- Authors
- Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J., Cho, M., & Hampel, H.
- Venue
- Nature Neuroscience
- Published
- 2024-06-19
- Volume
- 27
- Issue
- 7
- Pages
- 1236-1252
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W4399810054
- Cited by
- 66
- References
- 92
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.